

PATENT COOPERATION TREATY

AGBIOTECH IPM

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
**E.I. DU PONT DE NEMOURS AND COMPANY**  
 Legal/Patent Records Center  
 Attn. MAJARIAN, William R.  
 1007 Market Street  
 Wilmington, Delaware 19898  
 UNITED STATES OF AMERICA

**PCT**

NOTIFICATION OF TRANSMITTAL OF  
 THE INTERNATIONAL SEARCH REPORT  
 OR THE DECLARATION

**RECEIVED**

(PCT Rule 44.1)  
**FEB 17 2000**

**PATENT RECORDS  
 CENTER**

Date of mailing  
 (day/month/year)  
**07/02/2000**

Applicant's or agent's file reference <b>BB1167D</b>	<b>FOR FURTHER ACTION</b>	See paragraphs 1 and 4 below
International application No. <b>PCT/US 99/ 15812</b>	International filing date (day/month/year)	<b>13/07/1999</b>
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

1.  The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland  
 Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  <b>European Patent Office, P.B. 5818 Patentlaan 2    NL-2280 HV Rijswijk    Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,    Fax: (+31-70) 340-3016</b>	Authorized officer <b>Andria Overbeeke-Siepkes</b> <i>CLS NOTED    J. 18. Jan    misp</i>
--	---



## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

#### What documents must/may accompany the amendments?

**Letter (Section 205(b)):**

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.**



## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1167D</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 15812</b>	International filing date (day/month/year) <b>13/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/07/1998</b>
Applicant <b>E. I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

### 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1

None of the figures.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 partially

An isolated nucleic acid fragment encoding a rice sulfite reductase comprising a member selected from the group of: a fragment encoding an amino acid sequence that is at least 95% identical to the sequence set forth in SEQ ID NO:2 or a fragment complementary thereto. Said fragment optionally being RNA, preferably DNA as set forth in SEQ ID NO:1. Chimeric genes, transformed host cells, proteins derived therefrom. Use of said sequences for altering the level of expression of a sulfate assimilation protein in a host cell, and for diagnostic purposes. Products derived from said diagnostic screening studies.

2. Claims: 1-11 partially

idem for SEQ ID NO:3,4 (soybean)

3. Claims: 1-11 partailly

idem for SEQ ID NO:5,6 (wheat)



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/15812

## Box I Observation where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/15812

A. CLASSIFICATION OF SUBJECT MATTER	IPC 7	C12N15/53	C12N15/82	C12N9/02	C12N5/10	C12Q1/68
-------------------------------------	-------	-----------	-----------	----------	----------	----------

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SASAKI T.: "Rice cDNA from callus, EST AC C27405" EMBL DATABASE, 6 August 1997 (1997-08-06), XP002121812 Heidelberg the whole document ---	1,2,4,5, 10,11
X	MBEGUIE-A-MBEGUIE D. ET AL.: "AC AF071890; AC 081362" EMBL DATABASE, 29 June 1998 (1998-06-29), XP002128211 Heidelberg the whole document ---	6
A	---	1-5,7-11 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 January 2000

Date of mailing of the international search report

07.02.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T



## INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/15812

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IDEGUCHI T. ET AL.: "AC D50679; AC 023813" EMBL DATABASE, 1 January 1998 (1998-01-01), XP002128212 Heidelberg the whole document ---	6
A	BORK C ET AL: "Isolation and characterization of a gene for assimilatory sulfite reductase from <i>Arabidopsis thaliana</i> " GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 212, no. 1, 28 May 1998 (1998-05-28), page 147-153 XP004122435 ISSN: 0378-1119	1-5,7-11
A	the whole document ---	1-5,7-11
X	BRÜHL A. ET AL.: "A cDNA clone from <i>Arabidopsis thaliana</i> encoding plastidic ferredoxin: sulfite reductase" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1295, 1996, pages 119-124, XP002121813	6
A	the whole document ---	1-5,7-11
A	DATABASE WPI Section Ch, Week 199440 Derwent Publications Ltd., London, GB; Class C12, Page 6, AN 1994-321282 XP002121814 & JP 62 455773 A (MITSUBISHI CORP.), 6 September 1994 (1994-09-06) abstract -----	1-11



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 99/15812

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 62455773 A		NONE	



# PATENT COOPERATION TREATY

AGENOTECH IPM

From the INTERNATIONAL SEARCHING AUTHORITY

**PCT**

To:  
**E.I. DU PONT DE NEMOURS AND COMPANY**  
 Legal/Patent Records Center  
 Attn. MAJARIAN, W.  
 1007 Market Street  
 Wilmington, Delaware 19898  
 UNITED STATES OF AMERICA

**RECEIVED**  
 NOTIFICATION OF TRANSMITTAL OF  
 THE INTERNATIONAL SEARCH REPORT  
 OR THE DECLARATION

MAR 01 2000

(PCT Rule 44.1)

PATENT RECORDS  
 CENTER

Date of mailing  
 (day/month/year)

23/02/2000

Applicant's or agent's file reference  <b>BB1167</b>	<b>FOR FURTHER ACTION</b> <span style="float: right;">See paragraphs 1 and 4 below</span>
International application No.  <b>PCT/US 99/ 15810</b>	International filing date (day/month/year) <span style="float: right;"><b>13/07/1999</b></span>
Applicant  <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>	

1.  The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland  
 Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau.

If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority   <b>European Patent Office, P.B. 5818 Patentlaan 2    NL-2280 HV Rijswijk    Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,    Fax: (+31-70) 340-3016</b>	Authorized officer  <b>Mireille Claudepierre</b> <span style="float: right;"><b>CLS NOTED</b>  <i>J. 2. 2000</i></span>
--	---



## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the International application is English, the letter must be in English; if the language of the International application is French, the letter must be in French.**



## NOTES TO FORM PCT/ISA/220 (continu d)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1167</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 15810</b>	International filing date (day/month/year) <b>13/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/07/1998</b>
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

### 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

### 4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

### 5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

### 6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1

None of the figures.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/15810

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 partially

An isolated nucleic acid fragment encoding a corn sulfate permease comprising a member selected from the group of: a fragment encoding an amino acid sequence that is at least 85% identical to the sequence set forth in SEQ ID NO:2,4,6, or a fragment complementary thereto. Said fragment optionally being RNA, preferably selected from SEQ ID NO:1,3,5. Chimeric genes, transformed host cells, proteins derived therefrom. Use of said sequences for altering the level of expression of a sulfate assimilation protein in a host cell, and for diagnostic purposes. Products derived from said diagnostic screening studies.

2. Claims: 1-11 partially

idem for SEQ ID NO:7,8 (artichoke)

3. Claims: 1-11 partially

idem for SEQ ID NO:9-14 (rice)

4. Claims: 1-11 partially

idem for SEQ ID NO:15-18 (soybean)

5. Claims: 1-11 partially

idem for SEQ ID NO:19-22 (wheat)



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/15810A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/29 C12N15/82 C12N5/10 C12Q1/68 C07K14/415

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category <sup>a</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SMITH F. ET AL.: "Regulation of expression of a cDNA from barley roots encoding a high affinity sulphate transporter" PLANT JOURNAL, vol. 12, no. 4, 1997, pages 875-884, XP002129909. the whole document ---	6,10,11
X	SOHLBERG L. AND SUSSEX I.: "AC D89631" EMBL DATABASE, 1997, XP002129910. Heidelberg the whole document ---	6,10,11 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 February 2000

Date of mailing of the international search report

23.02.00

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15810

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FEDERSPIEL N. ET AL.: "AC 049307" EMBL DATABASE, June 1998 (1998-06), XP002129911 eidelberg the whole document ---	6,10,11
X	MINOBE Y. AND SASAKI T.: "AC D25000" EMBL DATABASE, 1993, XP002129912 Heidelberg the whole document ---	1,2,4-6, 10,11
X	BOLCHI A. ET AL.: "AC AF016306; AC 048889" EMBL DATABASE, 8 January 1998 (1998-01-08) - 1 June 1998 (1998-06-01), XP002121790 Heidelberg the whole document ---	10,11
X	NG A. ET AL.: "AC X96761; sulfate transporter from <i>Sporobolus stapfianus</i> " EMBL DATABASE, 1997, XP002121791 Heidelberg the whole document ---	10,11
X	TAKAHASHI H ET AL: "Regulation of sulfur assimilation in higher plants: a sulfate transporter induced in sulfate-starved roots plays a central role in <i>Arabidopsis</i> <i>thaliana</i> ." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 SEP 30) 94 (20) 11102-7., XP002121792 the whole document ---	10,11
A	TAKAHASHI, HIDEKI ET AL: "Antisense repression of sulfate transporter in transgenic <i>Arabidopsis thaliana</i> plants." PLANT AND CELL PHYSIOLOGY, (1998) VOL. 39, NO. SUPPL., PP. S148. MEETING INFO.: 1998 ANNUAL MEETING OF THE JAPANESE SOCIETY OF PLANT PATHOLOGISTS TOKYO, JAPAN MAY 3-5, 1998 JAPANESE SOCIETY OF PLANT PATHOLOGISTS., XP002121793 the whole document ---	1-11
A	SMITH F. ET AL.: "Plant members of a family of sulfate transporters reveal functional subtypes" PNAS, U.S.A., vol. 92, 1995, pages 9373-9377, XP002129913 the whole document -----	1-6



PATENT COOPERATION TREATY

AGRIOTECH IPM

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:  
E.I. DU PONT DE NEMOURS AND COMPANY  
Legal/Patent Records Center  
1007 Market Street  
Wilmington, Delaware 19898  
UNITED STATES OF AMERICA

WRM

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

RECEIVED

MAR 01 2000 (PCT Rule 44.1)

PATENT RECORDS  
CENTER

Date of mailing  
(day/month/year)

23/02/2000

Applicant's or agent's file reference BB1167E	FOR FURTHER ACTION      See paragraphs 1 and 4 below
International application No. PCT/US 99/ 15872	International filing date (day/month/year)      13/07/1999
Applicant E.I. DU PONT DE NEMOURS AND COMPANY et al.	

1.  The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer  
Barbara Klaver

CLS NOTED

BN

3.2.2000  
MUSP



## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the International application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.**



## NOTES TO FORM PCT/ISA/220 (continu d)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1167E</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 15872</b>	International filing date (day/month/year) <b>13/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/07/1998</b>
Applicant <b>E. I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  **Certain claims were found unsearchable (See Box I).**

3.  **Unity of invention is lacking (see Box II).**

4. With regard to the **title**,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1

None of the figures.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 15872

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 partially

An isolated nucleic acid fragment encoding a corn serine O-acetyltransferase comprising a member selected from the group of: a fragment encoding an amino acid sequence that is at least 90% identical to the sequence set forth in SEQ ID NO:2,4 or a fragment complementary thereto. Said fragment optionally being RNA, preferably selected from SEQ ID NO:1,3. Chimeric genes, transformed host cells, proteins derived therefrom. Use of said sequences for altering the level of expression of a sulfate assimilation protein in a host cell, and for diagnostic purposes. Products derived from said diagnostic screening studies.

2. Claims: 1-11 partially

idem for SEQ ID NO:5,6 (Impatiens)

3. Claims: 1-11 partially

idem for SEQ ID NO:7-10 (rice)

4. Claims: 1-11 partially

idem for SEQ ID NO:11-14 (soybean)

5. Claims: 1-11 partially

idem for SEQ ID NO:15,16 (wheat)



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15872

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/82 C12N9/10 C12N5/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAITO K. ET AL.: "Molecular cloning and characterization of a plant serine acetyltransferase playing a regulatory role in cysteine biosynthesis from watermelon" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 27, 1995, pages 16321-16326, XP002115631 the whole document ---	6,10,11
X	ROBERTS M. ET AL.: "Cloning and characterization of an Arabidopsis thaliana cDNA clone encoding an organellar isoform of serine acetyltransferase" PLANT MOLECULAR BIOLOGY, vol. 30, 1996, pages 1041-1049, XP002115633 the whole document ---	10,11
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

25 January 2000

Date of mailing of the international search report

23.02.2000

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

## Authorized officer

Kania, T



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/15872

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SASAKI T.: "AC C26373" EMBL DATABASE, 6 August 1997 (1997-08-06), XP002128627 Heidelberg the whole document ---	1,2,4-6, 10,11
X	SAITO K. AND TAKAGI Y.: "AC P93544" EMBL DATABASE, 1 May 1997 (1997-05-01), XP002128628 Heidelberg the whole document ---	6,10,11
A	YOO B. AND HARMON A.: "Regulation of recombinant soybean serine acetyltransferase by CDPK" PLANT PHYSIOLOGY SUPPL., vol. 114, 1997, page 267 XP002128629 abstract ---	1-11
A	SAITO K. ET AL.: "Molecular characterization of cysteine biosynthetic enzymes in plants" COMPTES RENDUS DE L'ACADEMIE DES SCIENCES, vol. 319, - 1996 pages 969-973, XP002121795 the whole document ---	1-11
A	SAITO ET AL: "Modulation of cysteine biosynthesis in chloroplasts of transgenic tobacco overexpressing cysteine synthase (O-Acetylserine(thiol) -lyase)" PLANT PHYSIOLOGY, no. 106, 1 January 1994 (1994-01-01), page 887 895 XP002078205 ISSN: 0032-0889 the whole document ---	1-11
A	SAITO K.: "Molecular aspects of sulfur assimilation and acclimation to sulfur supply in plants" STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, 1998, pages 215-226, XP002121796 the whole document ---	1-11
P,X	YAMAMOTO K AND SASAKI T.: "AC AU068082" EMBL DATABASE, 7 June 1999 (1999-06-07), XP002128630 Heidelberg the whole document ---	1,2,4-6, 10,11
P,X	YU Y. ET AL.: "AC AQ688702" EMBL DATABASE, 2 July 1999 (1999-07-02), XP002128631 Heidelberg the whole document -----	1,2,4-6, 10,11



PATENT COOPERATION TREATY

AGBIOTECH IPM

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:  
 E.I. DU PONT DE NEMOURS AND COMPANY  
 Legal/Patent Records Center  
 Attn. MAJARIAN, William R.  
 1007 Market Street  
 Wilmington, Delaware 19898  
 UNITED STATES OF AMERICA

RECEIVED  
 NOTIFICATION OF TRANSMITTAL OF  
 THE INTERNATIONAL SEARCH REPORT  
 OR THE DECLARATION

DEC 09 1999

(PCT Rule 44.1)

PATENT RECORDS  
 CENTER

Date of mailing  
 (day/month/year)

03/12/1999

Applicant's or agent's file reference

BB1167C

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 99/ 15808

International filing date

13/07/1999

Applicant

E.I. DU PONT DE NEMOURS AND COMPANY et al.

1.  The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland  
 Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL-2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Mireille Claudepierre

CLS NOTED

12.16.98 M/S



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1167C</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 15808</b>	International filing date (day/month/year) <b>13/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/07/1998</b>
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  **Certain claims were found unsearchable** (See Box I).

3.  **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1

None of the figures.



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/15808

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 partially

Isolated nucleotide sequence from maize that encodes a peptide with APS reductase activity, namely SEQIDs 1 and 2; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.

2. Claims: 1-11 partially

Isolated nucleotide sequence from Impatiens that encodes a peptide with APS reductase activity, namely SEQIDs 3 and 4; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.

3. Claims: 1-11 partially

Isolated nucleotide sequences from soybean that encode for peptides with APS reductase activity, namely SEQIDs 5,7 and 6,8; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.

4. Claims 1-11 partially

Isolated nucleotide sequence from wheat that encodes a peptide with APS reductase activity, namely SEQIDs 9 and 10; the recombinant expression of the same and methods for altering the expression of the enzymes in a host cell and for obtaining related sequences.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15808

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12N5/10 C12Q1/68  
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category <sup>°</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEYTA, A., ET AL. : "sulfate reduction in higher plants: molecular evidence for a novel 5'-adenylylsulfate reductase" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 93, November 1996 (1996-11), pages 13383-13388, XP002122451 the whole document ---- -/-	1, 3-7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 November 1999	03/12/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Holtorf, S



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15808

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUTIERREZ-MARCOS, J.F., ET AL. : "three members of a novel small gene-family from <i>Arabidopsis thaliana</i> able to complement functionally an <i>Escherichia coli</i> mutant defective in PAPS reductase activity encode proteins with a thioredoxin-like domain and "APS reductase" activity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 93, November 1996 (1996-11), pages 13377-13382, XP002122426 the whole document ---	1,3-7
A	BICK, J-A., ET AL. : "Glutaredoxin function for the carboxyl-terminal domain of the plant-type 5'-adenylylsulfate reductase" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 95, 7 July 1998 (1998-07-07), pages 8404-8409, XP002122450 the whole document ---	1
A	BICK, J.A. AND LEUSTEK, T.: "plant sulfur metabolism - reduction of sulfate to sulfite" CURRENT OPINION IN PLANT BIOLOGY, vol. 1, no. 3, June 1998 (1998-06), pages 240-244, XP000853523 the whole document ---	1
A	WRAY, J.L., ET AL. : "redefining reductive sulfate assimilation in higher plants: a role for APS reductase, a new member of the thioredoxin superfamily" CHEM BIOL INTERACTION, vol. 109, no. 1-3, February 1998 (1998-02), pages 153-167, XP000856016 the whole document ---	1-11
P, X	HEISS, S., ET AL. : "cloning sulfur assimilation genes from <i>Brassica juncea</i> L.: cadmium differentially affects the expression of a putative low-affinity sulfate transporter and isoforms of ATP sulfurylase and APS reductase" PLANT MOLECULAR BIOLOGY, vol. 39, March 1999 (1999-03), pages 847-857, XP002122448 abstract, Fig.3 --- -/-	1,3



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/15808

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	PRIOR, A., ET AL. : "structural and kinetic properties of adenylyl sulfate reductase from Catharanthus roseus cell cultures" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1430, no. 1, February 1999 (1999-02), pages 25-38, XP000853820 the whole document -----	1,4-6



# INTERNATIONAL SEARCH REPORT

Interr. Application No.  
PCT/US 99/15809

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/82 C12N9/12 C12N5/10 C12Q1/68  
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARZ, H.E., ET AL. : "a cDNA for adenylyl sulphate (APS)-kinase from <i>Arabidopsis thaliana</i> " BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1218, no. 3, August 1994 (1994-08), pages 447-452, XP000853818 cited in the application the whole document ---	1-11
A	BICK, J.A. AND LEUSTEK, T.: "plant sulfur metabolism - reduction of sulfate to sulfite" CURRENT OPINION IN PLANT BIOLOGY, vol. 1, no. 3, June 1998 (1998-06), pages 240-244, XP000853523 the whole document ---	1-11 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 November 1999

Date of mailing of the international search report

07/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

## INTERNATIONAL SEARCH REPORT

Intern	1st Application No
PCT/US 99/15809	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHIFFMANN, S. & SCHWENN, J.D.: "APS-sulfotransferase activity is identical to APS-kinase (EC 2.7.1.25)" FEBS LETTERS, vol. 355, 1994, pages 229-232, XP002122477 / the whole document ---	1-11
A	JAIN, A. & LEUSTEK, T.: "a cDNA clone for 5'-adenylylphosphosulfate kinase from <i>Arabidopsis thaliana</i> " PLANT PHYSIOLOGY, vol. 105, 1994, pages 771-772, XP002122478 the whole document ---	1-11
A	CHEN, Y. & LEUSTEK, T.: "sulfate-regulated expression of ATP sulfurylase and Adenosine-5'-phosphosulfate kinase in <i>brassica juncea</i> " PLANT PHYSIOLOGY - SUPPLEMENT, vol. 108, no. 2, June 1995 (1995-06), page 72 XP002122479 the whole document ---	1-11
A	LEE, S. AND LEUSTEK, T.: "APS kinase from <i>Arabidopsis thaliana</i> : genomic organization, expression, and kinetic analysis of the recombinant protein" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 247, 9 June 1998 (1998-06-09), pages 171-175, XP002122480 the whole document ---	1-11
P, X	WALBOT, V.: "maize ESTs from various cDNA libraries sequenced at Stanford University" EMBL SEQUENCE DATA LIBRARY, 27 April 1999 (1999-04-27), XP002123195 / heidelberg, germany accession no. AI637166 -----	1

## PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 20 March 2000 (20.03.00)	
International application No. PCT/US99/15809	Applicant's or agent's file reference BB1167B
International filing date (day/month/year) 13 July 1999 (13.07.99)	Priority date (day/month/year) 14 July 1998 (14.07.98)
Applicant FALCO, Saverio, Carl et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

07 February 2000 (07.02.00)

in a notice effecting later election filed with the International Bureau on:

\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Céline Faust
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

FEULNER, G.J.  
E.I. DU PONT DE NEMOURS AND COMPANY  
Legal/Patent Records Center  
1007 Market Street  
Wilmington, Delaware 19898  
ETATS-UNIS D'AMERIQUE

PCT

RECEIVED  
OCT 24 2000  
PATENT RECORDS  
CENTER

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year) 18.10.2000

Applicant's or agent's file reference  
BB1167B

IMPORTANT NOTIFICATION

International application No. PCT/US99/15809	International filing date (day/month/year) 13/07/1999	Priority date (day/month/year) 14/07/1998
---	--	--

Applicant

E.I. DU PONT DE NEMOURS AND COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

TRB NOTED


Name and mailing address of the IPEA/  
European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Vullo, C

Tel. +49 89 2399-8061





## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the International application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

**When?** Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

**How?** Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

#### What documents must/may accompany the amendments?

**Letter (Section 205(b)):**

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.**



## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]: "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



## PATENT COOPERATION TREATY

## PCT

B/1  
INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1167B</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 15809</b>	International filing date (day/month/year) <b>13/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>14/07/1998</b>
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1


None of the figures.



## PATENT COOPERATION TREATY

15

PCT




## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BB1167B	<b>FOR FURTHER ACTION</b> <small>See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)</small>	
International application No. PCT/US99/15809	International filing date (day/month/year) 13/07/1999	Priority date (day/month/year) 14/07/1998
International Patent Classification (IPC) or national classification and IPC C12N15/54		
Applicant E.I. DU PONT DE NEMOURS AND COMPANY et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>		

Date of submission of the demand 07/02/2000	Date of completion of this report 18.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Grosskopf, R Telephone No. +49 89 2399 8714





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/15809

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-22 as originally filed

### Claims, No.:

1-11 as originally filed

### Drawings, sheets:

1/2-2/2 as originally filed

2. The amendments have resulted in the cancellation of:

the description,      pages:  
 the claims,      Nos.:  
 the drawings,      sheets:

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

restricted the claims.  
 paid additional fees.  
 paid additional fees under protest.  
 neither restricted nor paid additional fees.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/15809

2.  This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
  - complied with.
  - not complied with for the following reasons:  
**see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
  - all parts.
  - the parts relating to claims Nos. 1-11 (all partially).


**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims 1-5,7-9
	No:	Claims 6,10,11
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-5,7-9
Industrial applicability (IA)	Yes:	Claims 1-11
	No:	Claims

2. Citations and explanations

**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/15809

**Ad item IV:**

As already indicated by the search examiner, the present set of claims lacks unity since the six different APS kinases claimed lack a common special feature, i.e. a feature which is common to all claimed kinases and which distinguishes them from the prior art (i.e. the prior art sequences SEQ ID NOs: 13 and 14).

Therefore, the present set of claims comprises six different (alleged) inventions, namely the claims insofar as they relate to SEQ ID NO: 2, 4, 6, 8, 10 or 12 respectively.

Since no response was made by the Applicant, the examination will be carried out with respect to group 1 i.e. claims relating to SEQ ID NOs: 1 and 2, as indicated in form 405.

**Ad item V:**

As indicated above, the nucleic acids for two APS kinases from *Catharanthus roseus* and from *Arabidopsis thaliana* are known.

Especially when considering that probes can easily be created on the basis of the knowledge of conserved regions in these two genes, the isolation of further genes encoding APS kinases from other plants is devoid of any inventive merit.

The same applies for the use of said genes or even the use of fragments thereof.

Therefore, none of the claims as presently on file fulfills the requirements of Article 33.3 PCT.

Moreover, claims relating to the APS kinase itself are not even novel since they comprise subparts of the complete sequences ("substantial portion"; see Claim 6) which are not distinguishable from the prior art or even comprise the products of the prior art (see Claims 10 and 11 since the APS kinases of the art are also obtainable by the methods of Claim 8 and 9).



**INTERNATIONAL SEARCH REPORT**

Int. application No.  
PCT/US 99/15809

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.



**INTERNATIONAL SEARCH REPORT**

International Application No. PCT/ US 99/15809

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

**1. Claims: 1-11 partially**

Isolated nucleotide sequences from maize that encode for peptides with APS kinase activity, namely SEQISs 1,3 and 2,4; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.

**2. Claims: 1-11 partially**

Isolated nucleotide sequence from rice that encodes a peptide with APS kinase activity, namely SEQIDs 5 and 6; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining sequences

**3. Claims: 1-11 partially**

Isolated nucleotide sequence from soybean that encodes a peptide with APS kinase activity, namely SEQIDs 7 and 8; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.

**4. Claims: 1-11 partially**

Isolated nucleotide sequences from wheat that encode for peptides with APS kinase activity, namely SEQIDs 9,11 and 10,12; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.



## INTERNATIONAL SEARCH REPORT

Int. application No.

PCT/US 99/ 15809

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International Application No. PCT/ US 99/15809

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 partially  
Isolated nucleotide sequences from maize that encode for peptides with APS kinase activity, namely SEQISs 1,3 and 2,4; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.
2. Claims: 1-11 partially  
Isolated nucleotide sequence from rice that encodes a peptide with APS kinase activity, namely SEQIDs 5 and 6; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining sequences
3. Claims: 1-11 partially  
Isolated nucleotide sequence from soybean that encodes a peptide with APS kinase activity, namely SEQIDs 7 and 8; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.
4. Claims: 1-11 partially  
Isolated nucleotide sequences from wheat that encode for peptides with APS kinase activity, namely SEQIDs 9,11 and 10,12; the recombinant expression of the same and methods for altering the expression of the enzyme in a host cell and for obtaining related sequences.



PCT

**WORLD INTELLECTUAL PROPERTY ORGANIZATION**  
**International Bureau**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(54) Title: GENES ENCODING SULFATE ASSIMILATION PROTEINS

**(57) Abstract**

This invention relates to an isolated nucleic acid fragment encoding a sulfate assimilation protein. The invention also relates to the construction of a chimeric gene encoding all or a portion of the sulfate assimilation protein, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the sulfate assimilation protein in a transformed host cell.

```

1          60
SEQ ID NO:2 RPFHEIMOTEPLVTHZTOOPPSPAAPGASO--CGROCHTLLSPTPLAVLIVNPORAPPVLP
SEQ ID NO:4
SEQ ID NO:6
SEQ ID NO:8 -ARATAKALRQPCYAGIYRTEC--GSPSSAELSGFPKLKG--INV
SEQ ID NO:10 -TNAODGERMA--G
SEQ ID NO:12 T
SEQ ID NO:13 -MIGSVKPNVSCVLPFEDPTTESTGLGKSSSVKLPUHFG--APG
SEQ ID NO:14 -MIAAGAKSLL--GLSHASPK--G--IPD

61          120
SEQ ID NO:2 SAA--AAVAGICSSSSA-
SEQ ID NO:4 GLTPSDAPLFLPAVHGILPTSSHSSAGLASDSSGRREGEGRGARTNCHRG1GRMVRRRRM
SEQ ID NO:6
SEQ ID NO:8 TGJHCGRGLVILVIRANSKPIRAKEM--ASVASSLID--DNFKPITAKED--S
SEQ ID NO:10 -S--VFPVAVAVAGKPC--VHG
SEQ ID NO:12
SEQ ID NO:13 SGG--GEVFLGLPFLAPIKATEGSKTS--FONGVKNVNFRNLOPSDCNS--S

```

SEQ	ID	MO:2	121	180
SEQ	ID	MO:4	-LVTSTWKGSTNLIWHECATGKNEOGLLNGCVCVWITGLGSSK	
SEQ	ID	MO:6	GAAPGEAPHSVPKKEPKVNPNSHIGKSTNLWINDCLICOSDRNLLGKGCGVWITGLGSSK	
SEQ	ID	MO:8	-----SIVPKASHINLHICAVGDRKQDQHLLGKGCGVWITGLGSSK	
SEQ	ID	MO:10	MAE-DTTSAPSGKMLTQNSWVHITLHIMQDPTQHQDRQDQHLLGKGCGVWITGLGSSK	
SEQ	ID	MO:12	-----SAMAGIDKLVTSTVKGSTNLWINDCPIQFGEFNEQELLHQKGCGVWITGLGSSK	
SEQ	ID	MO:13	DSSLWNCNGFPCKEILLOTTWYHSTNLWINDCAVEKSEVSEVWITGLGSSK	
SEQ	ID	MO:16	-----YHQTGQKGPKLPTVYDWTWYHSTNLWINDCAVEKSEVSEVWITGLGSSK	

SEQ	ID	NO:	2	181	240
SEQ	ID	NO:	4	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	5	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	6	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	8	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	10	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	12	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	13	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	
SEQ	ID	NO:	14	STLACALSELSELGRGMILTYVLDGDNORHGLNRDLSDFGAEADRAENIRVGEVAKLFDAGC1	

SEQ ID NO: 2	241	300
SEQ ID NO: 4	ICIAISLISPYRSORSACRDLNPKHSTIIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	
SEQ ID NO: 6	ICIAISLISPYRDACRDLNPKHSTIIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	
SEQ ID NO: 8	ICIAISLISPYKRSRDLNPKHSTIIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	
SEQ ID NO: 10	ICIAISLISPYQKRSRDLNPKHSTIIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	
SEQ ID NO: 12	ICIAISLISPYRSERSACRDLNPKHSTIIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	
SEQ ID NO: 13	ICIAISLISPYRPPONCRSISLPEGOFIVLIVDPLVCEARDPGKLGYXIAKAGKKGFTG	

```

SEQ ID NO:2 301 344
SEQ ID NO:4 1DQDYEPPSDCE2IV1QCNHGDCPSPSMAGHVVSYLEHNGFLQD
SEQ ID NO:6 1DQDYEPPMKEV1W1QHNSDCEPSPKMAGHVVSYLEHNGFLQD
SEQ ID NO:8 1DQDYEPPCSCE2IV1QGQSDC1GKPSDHA1ZEY1VSYLEHNGFLQD
SEQ ID NO:10 1DQDYEPPSDC51V1QHAGDGC2P7PSKHA1ZEY1VSYLEHNGFLQD
SEQ ID NO:12 1DQDYEPP2VS1EY1VSYLEHNGFLQD
SEQ ID NO:13 1DQDYEPLK1E1S1GKKG2TSP1DIA1V1QH1DNGFLQD
SEQ ID NO:14 1DQDYEPLK1E1S1GKKG2TSP1DIA1V1QH1DNGFLQD

```

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE

## GENES ENCODING SULFATE ASSIMILATION PROTEINS

This application claims the benefit of U.S. Provisional Application No. 60/092,833, filed July 14, 1998.

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding sulfate assimilation proteins in plants and seeds.

BACKGROUND OF THE INVENTION

10 Sulfate assimilation is the process by which environmental sulfur is fixed into organic sulfur for use in cellular metabolism. The two major end products of this process are the essential amino acids cysteine and methionine. These amino acids are limiting in food and feed; they cannot be synthesized by animals and thus must be acquired from plant sources. Increasing the level of these amino acids in feed products is thus of major 15 economic value. Key to that process is increasing the level of organic sulfur available for cysteine and methionine biosynthesis.

Multiple enzymes are involved in sulfur assimilation. These include: High affinity sulfate transporter and low affinity sulfate transporter proteins which serve to transport sulfur from the outside environment across the cell membrane into the cell (Smith et al. (1995)

20 *PNAS* 92(20):9373-9377). Once sulfur is in the cell sulfate adenylyltransferase (ATP sulfurylase) (Bolchia et al. (1999) *Plant Mol. Biol.* 39(3):527-537) catalyzes the first step in assimilation, converting the inorganic sulfur into an organic form, adenosine-5' phospho-sulfate (APS). Next, several enzymes further modify organic sulfur for use in the biosynthesis of cysteine and methionine. For example, adenylylsulfate kinase (APS kinase), 25 catalyzes the conversion of APS to the biosynthetic intermediate PAPS (3'-phospho-adenosine - 5' phosphosulfate) (Arz et al. (1994) *Biochim. Biophys. Acta* 1218(3):447-452). APS reductase (5' adenylyl phosphosulphate reductase) is utilized in an alternative pathway, resulting in an inorganic but cellularly bound (bound to a carrier), form of sulfur (sulfite) (Setya et al. (1996) *PNAS* 93(23):13383-13388). Sulfite reductase further reduces the 30 sulfite, still attached to the carrier, to sulfide and serine O-acetyltransferase converts serine to O-acetylserine, which will serve as the backbone to which the sulfide will be transferred to from the carrier to form cysteine (Yonelcura-Sakakibara et al. (1998) *J. Biolchem.* 124(3):615-621 and Saito et al. (1995) *J. Biol. Chem.* 270(27):16321-16326).

35 As described, each of these enzymes is involved in sulfate assimilation and the pathway leading to cysteine biosynthesis, which in turn serves as an organic sulfur donor for multiple other pathways in the cell, including methionine biosynthesis. Together or singly these enzymes and the genes that encode them have utility in overcoming the sulfur limitations known to exist in crop plants. It may be possible to modulate the level of sulfur

containing compounds in the cell, including the nutritionally critical amino acids cysteine and methionine. Specifically, their overexpression using tissue specific promoters will remove the enzyme in question as a possible limiting step, thus increasing the potential flux through the pathway to the essential amino acids. This will allow the engineering of plant tissues with increases levels of these amino acids, which now often must be added as supplements to animal feed.

#### SUMMARY OF THE INVENTION

The instant invention relates to isolated nucleic acid fragments encoding sulfate assimilation proteins. Specifically, this invention concerns an isolated nucleic acid fragment 10 encoding an APS kinase and an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding an APS kinase. In addition, this invention relates to a nucleic acid fragment that is complementary to the nucleic acid fragment encoding APS kinase. An additional embodiment of the instant invention pertains to a polypeptide encoding all or a substantial portion of an APS kinase.

15 In another embodiment, the instant invention relates to a chimeric gene encoding an APS kinase, or to a chimeric gene that comprises a nucleic acid fragment that is complementary to a nucleic acid fragment encoding an APS kinase, operably linked to suitable regulatory sequences, wherein expression of the chimeric gene results in production of levels of the encoded protein in a transformed host cell that is altered (i.e., increased or 20 decreased) from the level produced in an untransformed host cell.

25 In a further embodiment, the instant invention concerns a transformed host cell comprising in its genome a chimeric gene encoding an APS kinase, operably linked to suitable regulatory sequences. Expression of the chimeric gene results in production of altered levels of the encoded protein in the transformed host cell. The transformed host cell can be of eukaryotic or prokaryotic origin, and include cells derived from higher plants and microorganisms. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

30 An additional embodiment of the instant invention concerns a method of altering the level of expression of an APS kinase in a transformed host cell comprising: a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding an APS kinase; and b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of APS kinase in the transformed host cell.

35 An addition embodiment of the instant invention concerns a method for obtaining a nucleic acid fragment encoding all or a substantial portion of an amino acid sequence encoding an APS kinase.

BRIEF DESCRIPTION OF THE  
DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

5 Figure 1 shows a comparison of the amino acid sequences of the sequences set forth in SEQ ID NOS:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOS:13 and 14 respectively).

10 Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

15

TABLE 1  
Sulfate Assimilation Proteins

Protein	Clone Designation	(Nucleotide)	SEQ ID NO: (Amino Acid)
APS kinase	cen3n.pk0088.b10	1	2
APS kinase	p0016.ctscj40rb	3	4
APS kinase	r10n.pk112.o11	5	6
APS kinase	sdp2c.pk013.a11	7	8
APS kinase	wr1.pk0101.e2	9	10
APS kinase	wre1n.pk0069.g5	11	12

20 The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Research* 13:3021-3030 (1985) and in the *Biochemical Journal* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

25 In the context of this disclosure, a number of terms shall be utilized. As used herein, a "nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. A nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C), with the nucleic acid fragments disclosed herein.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Preferred are those nucleic acid fragments whose nucleotide sequences encode amino acid sequences that are 80% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that

are 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are 95% identical to the amino acid sequences reported herein. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

5 A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST

10 (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes

15 comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a

20 nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed

25 sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

30

35 "Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid.

Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic nucleic acid fragments” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. “Chemically synthesized”, as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.

“Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream

elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed 5 of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most 10 times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have 15 identical promoter activity.

The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, 20 mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The 25 polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary 30 copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA 35 refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by

reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

5 The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to 10 regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of 15 suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

20 "Altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and 25 propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a 30 nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) 35 may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere 5 et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A 10 Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

Nucleic acid fragments encoding at least a portion of several sulfate assimilation 15 proteins have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent 20 protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other APS kinase enzymes, either as cDNAs or genomic 25 DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize 30 DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

35 In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer

is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow 5 the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. 10 Acad. Sci. USA* 86:5673; Loh et al. (1989) *Science* 243:217). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165).

Availability of the instant nucleotide and deduced amino acid sequences facilitates 15 immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1; Maniatis).

20 The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of APS kinase in those cells. This enzyme is involved in sulfate assimilation and the pathway leading to cysteine biosynthesis, which in turn serves 25 as an organic sulfur donor for multiple other pathways in the cell, including methionine biosynthesis. This enzyme and the gene(s) that encodes the protein has utility in overcoming the sulfur limitations known to exist in crop plants. It may be possible to modulate the level of sulfur containing compounds in the cell, including the nutritionally critical amino acids cysteine and methionine. Specifically, their overexpression using tissue specific promoters 30 will remove the enzyme in question as a possible limiting step, thus increasing the potential flux through the pathway to the essential amino acids. This will allow the engineering of plant tissues with increases levels of these amino acids, which now often must be added a supplements to animal feed.

Overexpression of the proteins of the instant invention may be accomplished by first 35 constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding

sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U. S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of

gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

5 The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require 10 the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening 15 large numbers of transformants. The nature of these screens will generally be chosen on practical grounds, and is not an inherent part of the invention. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of 20 samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the 25 these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory 30 sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded sulfate 35 assimilation protein. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

All or a substantial portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with

the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing

5 restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

10 The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4(1):37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of

15 individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

20 Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

25 In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Research* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

30 A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 114(2):95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nature Genetics* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a

35 nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the

region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these 5 genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149; Bensen et al. (1995) *Plant Cell* 7:75). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence 10 primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against 15 PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of 20 the instant polypeptides disclosed herein.

#### EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, 25 are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

#### EXAMPLE 1

30 Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones  
cDNA libraries representing mRNAs from various corn, rice, soybean and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2  
cDNA Libraries from Corn, Rice, Soybean and Wheat

Library	Tissue	Clone
cen3n	Corn ( <i>Zea mays</i> L.) endosperm stage 3 (20 days after pollination)*	cen3n.pk0088.b10
p0016	Corn ( <i>Zea mays</i> L.) pooled tassel shoots 0.1-1.4 cm	p0016.ctscj40rb
r10n	Rice ( <i>Oryza sativa</i> L.) 15 day leaf*	r10n.pk112.o11
sdp2c	Soybean ( <i>Glycine max</i> L.) developing pods 6-7 mm	sdp2c.pk013.a11
wr1	Wheat ( <i>Triticum aestivum</i> L.) root; 7 day old seedling, light grown	wr1.pk0101.e2
wre1n	Wheat ( <i>Triticum aestivum</i> L.) root; 7 day old etiolated seedling*	wre1n.pk0069.g5

\*These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

5           cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP\* XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP\* XR libraries are converted into plasmid 10 libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid 15 vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids. or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or 20 "ESTs"; see Adams et al., (1991) *Science* 252:1651). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

#### EXAMPLE 2

##### Identification of cDNA Clones

25           cDNA clones encoding sulfate assimilation proteins were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and

DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all 5 publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nature Genetics* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the 10 reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

### EXAMPLE 3

#### Characterization of cDNA Clones Encoding APS Kinase

The BLASTX search using the EST sequences from clones listed in Table 3 revealed 15 similarity of the polypeptides encoded by the cDNAs to APS kinase from *Catharanthus roseus* (NCBI Identifier No. gi 2832300) and *Arabidopsis thaliana* (NCBI Identifier No. gi 1076283). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or 20 contigs assembled from two or more ESTs ("Contig").

TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous to *Catharanthus roseus* and *Arabidopsis thaliana* APS Kinase

Clone	Status	BLAST pLog Score
cen3n.pk0088.b10	EST	88.30 (gi 2832300)
p0016.ctscj40rb	FIS	88.50 (gi 2832300)
r10n.pk112.o11	EST	52.30 (gi 1076283)
sdp2c.pk013.a11	FIS	97.30 (gi 2832300)
wr1.pk0101.e2	FIS	84.50 (gi 2832300)
wre1n.pk0069.g5	FIS	14.30 (gi 2832300)

25 Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOs:13 and 14 respectively). The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOs:13 and 14).

30

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Catharanthus roseus* and *Arabidopsis thaliana* APS Kinase

SEQ ID NO.	Percent Identity to
2	70% (gi 2832300)
4	52% (gi 2832300)
6	67% (gi 1076283)
8	56% (gi 2832300)
10	63% (gi 2832300)
12	63% (gi 2832300)

5

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of an APS kinase. These sequences represent the first corn, 10 rice, soybean and wheat sequences encoding APS kinase.

10

15 rice, soybean and wheat sequences encoding APS kinase.

EXAMPLE 4Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. 20 Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, 25 VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb SalI-NcoI promoter fragment of the maize 27 kD zein gene and 30

a 0.96 kb SmaI-SalI fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be

5 screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

10 The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al.

15 (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

20 The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat*

25 gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The

particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 5

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 5 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

10 Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with fluorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

15 Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

20 A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

25 To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µL spermidine (0.1 M), and 50 µL CaCl<sub>2</sub> (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can 30 be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

35 Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, 5 necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

10

#### EXAMPLE 6

##### Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using 15 oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 20 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium 25 bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase 30 (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can 35 then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 5 1, IPTG (isopropylthio- $\beta$ -galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50  $\mu$ L of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe 10 sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One  $\mu$ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

CLAIMS

What is claimed is:

1. An isolated nucleic acid fragment encoding an APS kinase comprising a member selected from the group consisting of:
  - 5 (a) an isolated nucleic acid fragment encoding an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10 and 12
  - (b) an isolated nucleic acid fragment that is complementary to (a).
- 10 2. The isolated nucleic acid fragment of Claim 1 wherein nucleic acid fragment is a functional RNA.
3. The isolated nucleic acid fragment of Claim 1 wherein the nucleotide sequence of the fragment comprises the sequence set forth in a member selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9 and 11.
- 15 4. A chimeric gene comprising the nucleic acid fragment of Claim 1 operably linked to suitable regulatory sequences.
5. A transformed host cell comprising the chimeric gene of Claim 4.
6. An APS kinase polypeptide comprising all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 20 6, 8, 10 and 12.
7. A method of altering the level of expression of a sulfate assimilation protein in a host cell comprising:
  - 25 (a) transforming a host cell with the chimeric gene of Claim 4; and
  - (b) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene

wherein expression of the chimeric gene results in production of altered levels of a sulfate assimilation protein in the transformed host cell.
8. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a sulfate assimilation protein comprising:
  - 30 (a) probing a cDNA or genomic library with the nucleic acid fragment of Claim 1;
  - (b) identifying a DNA clone that hybridizes with the nucleic acid fragment of Claim 1;
  - (c) isolating the DNA clone identified in step (b); and
  - 35 (d) sequencing the cDNA or genomic fragment that comprises the clone isolated in step (c)

wherein the sequenced nucleic acid fragment encodes all or a substantial portion of the amino acid sequence encoding a sulfate assimilation protein.

9. A method of obtaining a nucleic acid fragment encoding a substantial portion of an amino acid sequence encoding a sulfate assimilation protein comprising:

5 (a) synthesizing an oligonucleotide primer corresponding to a portion of the sequence set forth in any of SEQ ID NOs:1, 3, 5, 7, 9, and 11; and  
(b) amplifying a cDNA insert present in a cloning vector using the oligonucleotide primer of step (a) and a primer representing sequences of the cloning vector

wherein the amplified nucleic acid fragment encodes a substantial portion of an amino acid sequence encoding a sulfate assimilation protein.

10 10. The product of the method of Claim 8.

11. The product of the method of Claim 9.

Figure 1

SEQ ID NO:2 SEQ ID NO:4 SEQ ID NO:6 SEQ ID NO:8 SEQ ID NO:10 SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14	1	60
<pre>----- RPFHFINQTEPLVTHTQQPPSPAPGPASQ-GQRQGNTLLSPTPTLAVILVNPQRAPPVLP ----- -----ARATAKALRQPCYAGIFRNIEC-GPSAAESLGFPKLRG-----INV -----TRADAGERMA-----G T----- -----MIGSVKRPVVSCVLPEFDTESTGLGKSSSVKLPVNFG-----AFG -----MIAAGAKSLL-----GLSMASPK-----G-----IFD</pre>		
SEQ ID NO:2 SEQ ID NO:4 SEQ ID NO:6 SEQ ID NO:8 SEQ ID NO:10 SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14	61	120
<pre>----- AAVAGISSSSA----- GLTPSDAPLPALVIHGLPRSSHSSAGLASDSGRREGEGRGARTHCHRGIGRWRVRRRRRN ----- TGLHCGRRGLVLVLRASKPIRAKEN--ASVVASLID-DWFKPITAKED-----S SEA-----VPVVAVAAGKQP-----VNG----- ----- SGG--GEVKLGFLAPIKATEGSKTSS--FQVNGKVDNFRHLQPSDCNSN-----S SNSMSNSRSVVVVRAVCVSMDSQTLS--HNKNGSIPEVKSI-----</pre>		
SEQ ID NO:2 SEQ ID NO:4 SEQ ID NO:6 SEQ ID NO:8 SEQ ID NO:10 SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14	121	180
<pre>----- -----LVTSTVGKSTNILWHECAIGQKEROGLLNQKGCVVWITGLSGSGK GAAPGEAPHSPVKEKPVMSNIGKSTNILWHNCLIGQSDRQKLLGQKGCVVWITGLSGSGK ----- -----SIVPKASNIFWHDCAVGQADRQKLLKQKGCVVWITGLSGSGK NAE-DRTSSFSGKNLTQMSNVGNSTNIMWHDCPIQKQDRQQLLQQQGCVIWTGLSGSGK ----- -----SAMAGIDKLVSTVGKSTNVLWHDCPIQFERQELLNQKGCVVWITGLSGSGK ----- DSSLNNCNGFPGKKILQTTVGNSTNILWHKCAVEKSERQEPLQQRGCVIWTGLSGSGK ----- -----NGHTGQKQGPLSTVGNSTNIKWHECSVEKVDQRQLLDQKGCVIWTGLSGSGK</pre>		
SEQ ID NO:2 SEQ ID NO:4 SEQ ID NO:6 SEQ ID NO:8 SEQ ID NO:10 SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14	181	240
<pre>----- STLACALSRELHGRGHHTYVLDGDNLRHGLNRLSFGAEDRAENIRRGEVAKLFADAGL STLACALSRELHCRGHHTYVLDGDNLRHGLNRLSFAEDRAENIRRGEVAKLFADAGV ----- STLACTLDRELHTRGKLSYVLDGDNLRHGLNRLGFKAEADRAENIRKVGEVAKLFXDASL STIACALSQLHSKGKLSYILDGDNIRHGLNQDLSFRAEDRSENIRRIGEVAKLFDAGV ----- STLACALSRELHSRGHHTYILDGDNLRHGLNRLDCFEAKDRAENIRRGEVAKLFADAGL ----- STLACALSRGLHAKGKHTYILDGDNVRHGLNSDLSFAEDRAENIRRIGEVAKLFDAGV ----- STLACALNQMLYQKGKLCYILDGDNVRHGLNRLSFAEDRAENIRRGEVAKLFADAGI</pre>		
SEQ ID NO:2 SEQ ID NO:4 SEQ ID NO:6 SEQ ID NO:8 SEQ ID NO:10 SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14	241	300
<pre>----- VCIASLISPYRSDRSACRDLLPKHSFIEVFLDVPLQVCEARDPKGLYKLARAGKIKGFTG ICIASLISPYRRDRDACPALLPHSNFIEVFIDPLKICEARDPKGLYKLARTGKIKGFTG VCIASFKSPYKRER----- ----- ICITSLISPYQKDRDACPALLSKGDFIEVFIDVPLHVCEARDPKGLYKLARAGKIKGFTG ICIASLISPYRSERSACRKLLHNSTFIEVFLNPLEVCEARDPKGLYKLARAGKIKGFTG ----- -----RLARTGKIKGFTG ICIASLISPYRKPPDACRSLLPEGDFIEVFMDVPLKVCEARDPKGLYKLARAGKIKGFTG ICIASLISPYRTDRDACPSSLPEGDFVEVFMDVPLSVCEARDPKGLYKLARAGKIKGFTG</pre>		

2010 RELEASE UNDER E.O. 14176

## Figure 1 (cont'd.)

	301	344
SEQ ID NO:2	IDDPYEPPSDCEIVI QCKVGDCPSPESMAGHVVSYLETNGFLQD	
SEQ ID NO:4	IDDPYEPPINGEIVI KMKDEECPSPKAMAKQVLCYLEENGYLQA	
SEQ ID NO:6	-----	-----ES
SEQ ID NO:8	IDDPYEPPCSCEIVLQQKGSDCKSPSDMAEEVISYLEENGYLRA	
SEQ ID NO:10	IDDPYEAPS DCEIVI QCKAGDCATPKSMADQVVSYLEANEFLQE	
SEQ ID NO:12	VDDPYESPVNSEIVI KMEGGECPSPKAMAQVQLSYLEKNGYLQA	
SEQ ID NO:13	IDDPYEPPLKSEIVLHQKLGMCDSPCDLADIVISYLEENGYLKA	
SEQ ID NO:14	IDDPYEPPLNCEISLGREGG--TSPIMAEKVVGYLDNKGYLQA	

02940000101110 61 DEU6000

WO 00/04165

PCT/US99/15809

SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company  
<120> Genes Encoding Sulfate Assimilation Proteins  
<130> BB-1167-B  
<140>  
<141>

<150> 60/092,833  
<151> July 14, 1998

<160> 14

<170> Microsoft Office 97

<210> 1  
<211> 890  
<212> DNA  
<213> Zea mays

<400> 1  
ggtcagcggc ggcggccgtc gcagggatca gcagcagcaq cagcgcgctg gtgacacctga 60  
ccgtcgggaa atcgacgaac atcctgtggc atgagtgcgc catcgccgac aaggagcgac 120  
agggtctgtc gaaccagaag ggctgcgtcg tggatcac tggcttaagc gttcaggga 180  
aaagcacgtc cgcgtgcgcg ctgagccgcg agctgcacgg cagaggccac ctcacgtacg 240  
tcctcgacgg cgacaacctc aggacacgggc tgaacaggga cctcagcttc ggagcagagg 300  
accgcgcgca gaacatccgc agagtagggg aagttagcga qctgttcgcgc gacgctggcc 360  
tcgtctgcatt cgccagcctc atatcgccct acagaagcga ccgaagcgcg tgtcgcgatc 420  
tgctgccccaa gcactcgttt atcgaggtgt tcctggacgt gccgcttcaa gtgtgcgaag 480  
ccagggaccc caaaggcctc tacaagctcg cacgcgcggg caaaatcaaa gggttcacccg 540  
gcacgcacga tccttacgaa ccgcgtcg actgtgagat agtgatccag tgtaaagtgc 600  
gcgactgccc ttgcctgaa tcgatggctg gtcacgttgcgt gtcgtacctt gagacaatg 660  
gtttcctcca ggactagaca tggatgcga tcgatgcgtc tgatgtgtat atatgtgca 720  
gcagccggag cggcattgcc aaggctgtgt aatctcatgg ctgtcttct ctttaagacc 780  
aaaacaaaca agagatggca gtgtaaaaaa gaaaaaaaaa actgcgtctg acagagtcgc 840  
tgaatcaacc atgctctga taaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa 890

<210> 2  
<211> 224  
<212> PRT  
<213> Zea mays


<400> 2  
Ser Ala Ala Ala Ala Val Ala Gly Ile Ser Ser Ser Ser Ala Leu  
1 5 10 15

Val Thr Ser Thr Val Gly Lys Ser Thr Asn Ile Leu Trp His Glu Cys  
20 25 30

Ala Ile Gly Gln Lys Glu Arg Gln Gly Leu Leu Asn Gln Lys Gly Cys  
35 40 45

Val Val Trp Ile Thr Gly Leu Ser Gly Ser Gly Lys Ser Thr Leu Ala  
50 55 60

Cys Ala Leu Ser Arg Glu Leu His Gly Arg Gly His Leu Thr Tyr Val  
65 70 75 80



Leu Asp Gly Asp Asn Leu Arg His Gly Leu Asn Arg Asp Leu Ser Phe  
85 90 95

Gly Ala Glu Asp Arg Ala Glu Asn Ile Arg Arg Val Gly Glu Val Ala  
                  100                 105                 110

Lys Leu Phe Ala Asp Ala Gly Leu Val Cys Ile Ala Ser Leu Ile Ser  
 115 120 125

Pro Tyr Arg Ser Asp Arg Ser Ala Cys Arg Asp Leu Leu Pro Lys His  
130 135 140

Ser Phe Ile Glu Val Phe Leu Asp Val Pro Leu Gln Val Cys Glu Ala  
 145 150 155 160

Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala Arg Ala Gly Lys Ile Lys  
165 170 175

Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu Pro Pro Ser Asp Cys Glu  
                  180                 185                 190

Ile Val Ile Gln Cys Lys Val Gly Asp Cys Pro Ser Pro Glu Ser Met  
195 200 205

Ala Gly His Val Val Ser Tyr Leu Glu Thr Asn Gly Phe Leu Gin Asp  
210 215 220

<210> 3  
<211> 1217  
<212> DNA  
<213> Zea mays

```


<400> 3
gcgtccgttt catttcatca atcaaacaga acctctggtc acacacacgc agcaaccacc 60
gagcccagcg cccggcccgag ccagccaggg ccaacggcaa ggcaacacccc tcctcagccc 120
gacgcccacg ctgcggcgtca tcctcgtaaa tccacagcgc ggcgcctcccg tcctcccagg 180
cctcaccctt agcgatgcgc cactcccgcc gctcggtatc catggcctca ctcccggttc 240
ctcacactct tccgcgggtc tcgcccagtga tagtggggcgc cgcgagggggg agggccgcgg 300
tgcgcgtacg cactgccacc gggcattgg ggggtgggtg cggcggcggc ggcggaatgg 360
agcagcgcacc ggggaggccc cgcacagccc agtgaaggag aagcctgtaa tgcgaacat 420
tgggaaatcg actaatatattt tatggcacaat ttgcttgatt ggacaatctg atagacagaa 480
attgcgtggga caaaaaggct gtgtcgatg gataacagga ctcagtggtt cagggaaaag 540
tactcttgca tgcgtactga gtcgtgagtt gcattgcaga ggcacactca cgtatgtact 600
tgcgtgtgac aacctcagac atggcctaaa tagagattt agctttaagg cagaagaccc 660
tgcagaaaaat atacgaagag ttgggtgaagt ggcaagctt tttgctgtatc ctgggtgtcat 720
atgcattgtct agttgtatctt ctccatcacag gagagatcgt gatgcgtgcc gtgcgtctact 780
tccacattct aactttattt aagtattttat tgatttgcctt ctaaaaattt gtgaagctcg 840
tgcgtgttccaa ggccatacata agcttgcacg tacagggaaat attaaagggtt tcactggat 900
tgcgtgttccaa tgcgtgttccaa caattaaatgg tgagatagta attaagatga aagatgagga 960
atgcgtgttccaa cccaaaggcaat tggccaaagca agttctatgc taccttgaag aaaacggata 1020
tttgcgtgttccaa tagtataatgtt attttggatggatggatgtt gattgtatgc attcttgttgcgttgcattact 1080
tgcgtgttccaa ataagatctgtt tttgcgtgttccaa catgaataaaa aggcataac atgttaggaag 1140
taacagaagg tgcgtgttccaa tcagaaacgg atatggatttccat attcggtttaaa aaaaaaaaaaa 1200
aaaaaaaaaaaa aaaaaaaaaaa aaaaaaaaaaa aaaaaaaaaaa 1217

```

<210> 4  
<211> 343  
<212> PRT  
<213> Zea mays



<400> 4  
Arg Pro Phe His Phe Ile Asn Gln Thr Glu Pro Leu Val Thr His Thr  
1 5 10 15  
Gln Gln Pro Pro Ser Pro Ala Pro Gly Pro Ala Ser Gln Gly Gln Arg  
20 25 30  
Gln Gly Asn Thr Leu Leu Ser Pro Thr Pro Thr Leu Ala Val Ile Leu  
35 40 45  
Val Asn Pro Gln Arg Ala Pro Pro Val Leu Pro Gly Leu Thr Pro Ser  
50 55 60  
Asp Ala Pro Leu Pro Ala Leu Val Ile His Gly Leu Thr Pro Arg Ser  
65 70 75 80  
Ser His Ser Ser Ala Gly Leu Ala Ser Asp Ser Gly Arg Arg Glu Gly  
85 90 95  
Glu Gly Arg Gly Ala Arg Thr His Cys His Arg Gly Ile Gly Arg Trp  
100 105 110  
Val Arg Arg Arg Arg Asn Gly Ala Ala Pro Gly Glu Ala Pro His  
115 120 125  
Ser Pro Val Lys Glu Lys Pro Val Met Ser Asn Ile Gly Lys Ser Thr  
130 135 140  
Asn Ile Leu Trp His Asn Cys Leu Ile Gly Gln Ser Asp Arg Gln Lys  
145 150 155 160  
Leu Leu Gly Gln Lys Gly Cys Val Val Trp Ile Thr Gly Leu Ser Gly  
165 170 175  
Ser Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Glu Leu His Cys  
180 185 190  
Arg Gly His Leu Thr Tyr Val Leu Asp Gly Asp Asn Leu Arg His Gly  
195 200 205  
Leu Asn Arg Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn Ile  
210 215 220  
Arg Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val Ile  
225 230 235 240  
Cys Ile Ala Ser Leu Ile Ser Pro Tyr Arg Arg Asp Arg Asp Ala Cys  
245 250 255  
Arg Ala Leu Leu Pro His Ser Asn Phe Ile Glu Val Phe Ile Asp Leu  
260 265 270  
Pro Leu Lys Ile Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu  
275 280 285  
Ala Arg Thr Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr  
290 295 300



Glu Pro Pro Ile Asn Gly Glu Ile Val Ile Lys Met Lys Asp Glu Glu  
 305 310 315 320  
 Cys Pro Ser Pro Lys Ala Met Ala Lys Gln Val Leu Cys Tyr Leu Glu  
 325 330 335  
 Glu Asn Gly Tyr Leu Gln Ala  
 340

<210> 5  
 <211> 431  
 <212> DNA  
 <213> Oryza sativa

<220>  
 <221> unsure  
 <222> (48)

<220>  
 <221> unsure  
 <222> (346)

<220>  
 <221> unsure  
 <222> (431)

<400> 5  
 cttacacaga gatcaggtag aacagtggc gagaacaaag ttttgcattt gtcattttt 60  
 gtgcggagg cgtccatatat cttctggcat gatttgtcag ttggccaggc tgatcgccag 120  
 aagctactga agcagaaagg ttgcgttgg tggatcacag gacttagtgg ttcaaggtaaa 180  
 agtaccctgg catgcacatt agatcgagag ctccatacaa gagggaaagct t .cttatgtt 240  
 cttgatggtg ataatttaag acatggtttg aacaaggatc ttggctttaa ggcgaaagac 300  
 cgtgctgaaa atatacgcaa agttggtag gtagcaaagc tattcncaga tgcaagccta 360  
 gtatgcattt caagtttcaa atctccatat aagagagaac gtgagtcctt gcccctgcaat 420  
 attgtcaat n 431

<210> 6  
 <211> 118  
 <212> PRT  
 <213> Oryza sativa

<220>  
 <221> UNSURE  
 <222> (98)


<400> 6  
 Ser Ile Val Pro Lys Ala Ser Asn Ile Phe Trp His Asp Cys Ala Val  
 1 5 10 15

Gly Gln Ala Asp Arg Gln Lys Leu Leu Lys Gln Lys Gly Cys Val Val  
 20 25 30

Trp Ile Thr Gly Leu Ser Gly Ser Gly Lys Ser Thr Leu Ala Cys Thr  
 35 40 45

Leu Asp Arg Glu Leu His Thr Arg Gly Lys Leu Ser Tyr Val Leu Asp  
 50 55 60

Gly Asp Asn Leu Arg His Gly Leu Asn Lys Asp Leu Gly Phe Lys Ala  
 65 70 75 80



Glu Asp Arg Ala Glu Asn Ile Arg Lys Val Gly Glu Val Ala Lys Leu  
 85 90 95

Phe Xaa Asp Ala Ser Leu Val Cys Ile Ala Ser Phe Lys Ser Pro Tyr  
 100 105 110

Lys Arg Glu Arg Glu Ser  
 115

<210> 7  
 <211> 936  
 <212> DNA  
 <213> Glycine max

<400> 7  
 gcacqagcca ccgcgaaggc tctgcgacag ccctgctacg ccgaaatctt tcgcaacatc 60  
 gaatgcggcc cgtcgccggc ggcggagtcg cttagggttc cgaagctccg cgaaatcaac 120  
 gtcactggat tgcactgcgg ccgcccgggc ctcgtcctcg tcctccgtgc aaaatcaaag 180  
 ccgattaggg cgaaggagaa cgcgaagcgt agtgttctc tgatcgatga ctgggtcaag 240  
 ccaattacgg cgaaggagga ttctaacgca gaggaccgt aatcttcgtt ttctggtaaa 300  
 aatctcaccc agatgtcaaa tggatggaaac tcgacaaaca ttatgtggca tgactgtcca 360  
 attcagaaaac aagatagaca gcagctgtt cagcaacaag gctgtgttat atggctaact 420  
 ggcctcagcg gatcaggaaa aagcactatt gcatgtgctc tgagtcaaag cttgcactcc 480  
 aaaggaaaaac tgttttacat ctttgcgtt gacaatattc ggcatggct aaaccaggat 540  
 cttagtttta gaggcagaaga tcgttctgaa aacattagaa ggattggtga ggtggcaaaa 600  
 ctctttgcag atgctgggtt tatttgcattt actagttta tatcaccata ccaaaaggat 660  
 agagatgcattt gcaagactt actttcaaaa ggagatttt ttgaggtttt catagatgtt 720  
 ccactacatg tgtgtgaagc tagggaccca aaggactct acaagcttc tcgagctgga 780  
 aagatcaaaag gtttcaactgg tatacatgtt ccatatgaac caccgtgttag ttgtgagata 840  
 gtattacaac agaaaggaag tgactgttaag tctccagtg atitggctga agaagtgtata 900  
 tcctacttgg aggagaacgg atacctgcgg gcttga 936

<210> 8  
 <211> 311  
 <212> PRT  
 <213> Glycine max

<400> 8  
 Ala Arg Ala Thr Ala Lys Ala Leu Arg Gin Pro Cys Tyr Ala Gly Ile  
 1 5 10 15

Phe Arg Asn Ile Glu Cys Gly Pro Ser Pro Ala Ala Glu Ser Leu Gly  
 20 25 30


Phe Pro Lys Leu Arg Gly Ile Asn Val Thr Gly Leu His Cys Gly Arg  
 35 40 45

Arg Gly Leu Val Leu Val Leu Arg Ala Lys Ser Lys Pro Ile Arg Ala  
 50 55 60

Lys Glu Asn Ala Ser Val Ser Ala Ser Leu Ile Asp Asp Trp Phe Lys  
 65 70 75 80

Pro Ile Thr Ala Lys Glu Asp Ser Asn Ala Glu Asp Arg Thr Ser Ser  
 85 90 95

Phe Ser Gly Lys Asn Leu Thr Gln Met Ser Asn Val Gly Asn Ser Thr  
 100 105 110



Asn Ile Met Trp His Asp Cys Pro Ile Gln Lys Gln Asp Arg Gln Gln  
 115 120 125

Leu Leu Gln Gln Gln Gly Cys Val Ile Trp Leu Thr Gly Leu Ser Gly  
 130 135 140

Ser Gly Lys Ser Thr Ile Ala Cys Ala Leu Ser Gln Ser Leu His Ser  
 145 150 155 160

Lys Gly Lys Leu Ser Tyr Ile Leu Asp Gly Asp Asn Ile Arg His Gly  
 165 170 175

Leu Asn Gln Asp Leu Ser Phe Arg Ala Glu Asp Arg Ser Glu Asn Ile  
 180 185 190

Arg Arg Ile Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val Ile  
 195 200 205

Cys Ile Thr Ser Leu Ile Ser Pro Tyr Gln Lys Asp Arg Asp Ala Cys  
 210 215 220

Arg Ala Leu Leu Ser Lys Gly Asp Phe Ile Glu Val Phe Ile Asp Val  
 225 230 235 240

Pro Leu His Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu  
 245 250 255

Ala Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr  
 260 265 270


Glu Pro Pro Cys Ser Cys Glu Ile Val Leu Gln Gln Lys Gly Ser Asp  
 275 280 285

Cys Lys Ser Pro Ser Asp Met Ala Glu Glu Val Ile Ser Tyr Leu Glu  
 290 295 300

Glu Asn Gly Tyr Leu Arg Ala  
 305 310

<210> 9  
 <211> 928  
 <212> DNA  
 <213> Triticum aestivum

<400> 9  
 gcacgaggc ggacgcaggg gagaggatgg cgggtcaga agccgtgccg gtgggtggctg 60  
 tggctgccgg gaagcagccc gtcaatggat cagccatggc aggtatcgac aagcttgtga 120  
 cctcaactgt tggaaaatcg acaaacgttc tttggcatga ctgtccaata ggtcagttt 180  
 agaggcagga actgctaaat cagaagggtt gtgttgtgtg gataacaggg ttaagtggtt 240  
 caggaaaaag cacactagca tgcgcgctaa gtcgcgagct gcactccaga ggtcatctga 300  
 cctacattct agacggtgac aatctaaggc atgggttaaa ccgagacctc tggttcgaag 360  
 caaaggaccg tgctgaaaat atacgcagag taggagaagt agcaaagctg tttgcagatg 420  
 ctggtctgtat ctgcattgtct agcttgatat caccctacag aagtgaacgc agcgcttgcc 480  
 gcaaattact gcacaattct acattcatcg aggtgtttt gaatgtccca cttgaagttt 540  
 gtgaagctag ggatccaaaa ggcttgtaca agcttgcccg tgcaggaaaa atcaaagggt 600  
 ttactggaat tgatgtatct tatgaagcac cttctgactg cgagatagt atacagtgca 660  
 aagctggtga ctgcgccacg cctaaatcga tggctgtatca agttgtgtca tatcttgaag 720  
 caaatgagtt cttacaggaa tagagacgta tgctatggat gaaaaaacat tctgaaattg 780  
 gatcgccaaag ggtatgtaaa tatgaggtat tatttatgtc tagaaagagt gatgatagta 840  
 tgagaacata tatattgaca taaagatcga atctgtacat cattataata aattgaaatg 900



tttgacgca aaaaaaaaaa aaaaaaaaaa 928

<210> 10  
<211> 246  
<212> PRT  
<213> Triticum aestivum

<400> 10  
Thr Arg Ala Asp Ala Gly Glu Arg Met Ala Gly Ser Glu Ala Val Pro  
1 5 10 15

Val Val Ala Val Ala Ala Gly Lys Gln Pro Val Asn Gly Ser Ala Met  
20 25 30

Ala Gly Ile Asp Lys Leu Val Thr Ser Thr Val Gly Lys Ser Thr Asn  
35 40 45

Val Leu Trp His Asp Cys Pro Ile Gly Gln Phe Glu Arg Gln Glu Leu  
50 55 60

Leu Asn Gln Lys Gly Cys Val Val Trp Ile Thr Gly Leu Ser Gly Ser  
65 70 75 80

Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Glu Leu His Ser Arg  
85 90 95

Gly His Leu Thr Tyr Ile Leu Asp Gly Asp Asn Leu Arg His Gly Leu  
100 105 110

Asn Arg Asp Leu Cys Phe Glu Ala Lys Asp Arg Ala Glu Asn Ile Arg  
115 120 125

Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Leu Ile Cys  
130 135 140

Ile Ala Ser Leu Ile Ser Pro Tyr Arg Ser Glu Arg Ser Ala Cys Arg  
145 150 155 160

Lys Leu Leu His Asn Ser Thr Phe Ile Glu Val Phe Leu Asn Val Pro  
165 170 175

Leu Glu Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala  
180 185 190


Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu  
195 200 205

Ala Pro Ser Asp Cys Glu Ile Val Ile Gln Cys Lys Ala Gly Asp Cys  
210 215 220

Ala Thr Pro Lys Ser Met Ala Asp Gln Val Val Ser Tyr Leu Glu Ala  
225 230 235 240

Asn Glu Phe Leu Gln Glu  
245

<210> 11  
<211> 521  
<212> DNA  
<213> Triticum aestivum



<400> 11  
 gcacgaggctgcacgcaca ggaaagatta aagggttcac cggagtttat gatccatacg 60  
 aatcaccagt gaatagttag atagtaatata agatggaaagg tggggaatgc ctttcaccga 120  
 aggcaatggcccagcaagtt ctgtcctacc ttgagaagaa cggatatttgc caggcttgc 180  
 atatatatac tccagatcca gaagattgaa cttattcttc tgggtccata actcatggac 240  
 acaggcatga tccatttggt cgcattccgaa ataaaaggcg ctgttatttgc agcaacaagc 300  
 tgccttttc acggggaaag ggacgcagat cgatgatcag tttgatttgc cggcatttgc 360  
 cctctcgccgtgttttttgc attttagctg tagtctatac ttgctcattt cggctgaaat 420  
 ggtgtgctgt gctgtgctgt gtttatttgc tggtaatgtatgatttgc 480  
 aaagtacgaa tgaataaattc tgcattgcgt tttcaaaaaa a 521

<210> 12

<211> 58

<212> PRT

<213> *Triticum aestivum*

<400> 12

Thr	Arg	Leu	Ala	Arg	Thr	Gly	Lys	Ile	Lys	Gly	Phe	Thr	Gly	Val	Asp
1															
														15	

Asp	Pro	Tyr	Glu	Ser	Pro	Val	Asn	Ser	Glu	Ile	Val	Ile	Lys	Met	Glu
													30		

Gly	Gly	Glu	Cys	Pro	Ser	Pro	Lys	Ala	Met	Ala	Gln	Gln	Val	Leu	Ser
												45			

Tyr	Leu	Glu	Lys	Asn	Gly	Tyr	Leu	Gln	Ala
									55

<210> 13

<211> 312

<212> PRT

<213> *Catharanthus roseus*

<400> 13

Met	Ile	Gly	Ser	Val	Lys	Arg	Pro	Val	Val	Ser	Cys	Val	Leu	Pro	Glu
1															
													15		

Phe	Asp	Phe	Thr	Glu	Ser	Thr	Gly	Leu	Gly	Lys	Ser	Ser	Ser	Val
												30		

Lys	Leu	Pro	Val	Asn	Phe	Gly	Ala	Phe	Gly	Ser	Gly	Gly	Glu	Val
												45		


Lys	Leu	Gly	Phe	Leu	Ala	Pro	Ile	Lys	Ala	Thr	Glu	Gly	Ser	Lys	Thr
												60			

Ser	Ser	Phe	Gln	Val	Asn	Gly	Lys	Val	Asp	Asn	Phe	Arg	His	Leu	Gln
													80		


Pro	Ser	Asp	Cys	Asn	Ser	Asn	Ser	Asp	Ser	Ser	Leu	Asn	Asn	Cys	Asn
													95		

Gly	Phe	Pro	Gly	Lys	Lys	Ile	Leu	Gln	Thr	Thr	Thr	Val	Gly	Asn	Ser
												110			

Thr	Asn	Ile	Leu	Trp	His	Lys	Cys	Ala	Val	Glu	Lys	Ser	Glu	Arg	Gln
												125			



Glu Pro Leu Gln Gln Arg Gly Cys Val Ile Trp Ile Thr Gly Leu Ser  
 130 135 140  
 Gly Ser Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Gly Leu His  
 145 150 155 160  
 Ala Lys Gly Lys Leu Thr Tyr Ile Leu Asp Gly Asp Asn Val Arg His  
 165 170 175  
 Gly Leu Asn Ser Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn  
 180 185 190  
 Ile Arg Arg Ile Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val  
 195 200 205  
 Ile Cys Ile Ala Ser Leu Ile Ser Pro Tyr Arg Lys Pro Pro Asp Ala  
 210 215 220  
 Cys Arg Ser Leu Leu Pro Glu Gly Asp Phe Ile Glu Val Phe Met Asp  
 225 230 235 240  
 Val Pro Leu Lys Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys  
 245 250 255  
 Leu Ala Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro  
 260 265 270  
 Tyr Glu Pro Pro Leu Lys Ser Glu Ile Val Leu His Gln Lys Leu Gly  
 275 280 285  
 Met Cys Asp Ser Pro Cys Asp Leu Ala Asp Ile Val Ile Ser Tyr Leu  
 290 295 300  
 Glu Glu Asn Gly Tyr Leu Lys Ala  
 305 310  
 <210> 14  
 <211> 276  
 <212> PRT  
 <213> *Arabidopsis thaliana*  
 <400> 14  
 Met Ile Ala Ala Gly Ala Lys Ser Leu Leu Gly Leu Ser Met Ala Ser  
 1 5 10 15  
 Pro Lys Gly Ile Phe Asp Ser Asn Ser Met Ser Asn Ser Arg Ser Val  
 20 25 30  
 Val Val Val Arg Ala Cys Val Ser Met Asp Gly Ser Gln Thr Leu Ser  
 35 40 45  
 His Asn Lys Asn Gly Ser Ile Pro Glu Val Lys Ser Ile Asn Gly His  
 50 55 60  
 Thr Gly Gln Lys Gln Gly Pro Leu Ser Thr Val Gly Asn Ser Thr Asn  
 65 70 75 80  
 Ile Lys Trp His Glu Cys Ser Val Glu Lys Val Asp Arg Gln Arg Leu  
 85 90 95



Leu Asp Gln Lys Gly Cys Val Ile Trp Val Thr Gly Leu Ser Gly Ser  
100 105 110

Gly Lys Ser Thr Leu Ala Cys Ala Leu Asn Gln Met Leu Tyr Gln Lys  
115 120 125

Gly Lys Leu Cys Tyr Ile Leu Asp Gly Asp Asn Val Arg His Gly Leu  
130 135 140

Asn Arg Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn Ile Arg  
145 150 155 160

Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Ile Ile Cys  
165 170 175

Ile Ala Ser Leu Ile Ser Pro Tyr Arg Thr Asp Arg Asp Ala Cys Arg  
180 185 190

Ser Leu Leu Pro Glu Gly Asp Phe Val Glu Val Phe Met Asp Val Pro  
195 200 205

Leu Ser Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala  
210 215 220

Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu  
225 230 235 240

Pro Pro Leu Asn Cys Glu Ile Ser Leu Gly Arg Glu Gly Gly Thr Ser  
245 250 255

Pro Ile Glu Met Ala Glu Lys Val Val Gly Tyr Leu Asp Asn Lys Gly  
260 265 270

Tyr Leu Gln Ala  
275

